@DavidJCutter

Clinical Oncologist at Oxford Cancer Centre and Associate Professor at the University of Oxford. @ChelseaFC fan. Opinions are mine.

 Oxford, UK
Joined September 2011
  • Tweets532
  • Following419
  • Followers258
27Media
David Cutter retweeted
Graham Collins@graham74GCOct 3
The incredible @ABarrettHaem receiving an abstract away at #ISHL14 for her work on older Hodgkin patients. Richly deserved. 👏👏👏
7
2
42
2,611
David Cutter retweeted
Aisling Barrett@ABarrettHaemSep 15
New paper alert 👀 thank you to @Haematologica for publishing our analysis of ~30,000 UK classic Hodgkin lymphoma patients, with a focus on the ever-interesting older population. NB: anthracycline is key! haematologica.org/article/vi… @DavidJCutter @graham74GC
4
7
3
30
8,534
Our @glow_nlphl lead Dr. @JamieFlerlage spoke about the GLOW multicenter study of radiation therapy outcomes for Stage IA NLPHL which she presented at #18ICML for @VJHemOnc. #lymsm #NLPHLsm vjhemonc.com/video/amtyhj8pq…

Using radiotherapy to improve PFS for stage IA nodular lymphocyte-predominant Hodgkin lymphoma

Jamie Flerlage, MD, MS, University of Rochester, Rochester, NY, comments on the impact of radiation therapy on progression-free survival (PFS) in patients with stage IA nodular lymphocyte-predominant...

vjhemonc.com
4
12
779
If you’re at #ICML2025 come by my poster 1230-1300. We examine survival by anthracycline use in older cHL patients. TLDR: use anthracycline if at all possible! @DavidJCutter @graham74GC
2
8
46
2,655
View the latest NNHLA Quarterly Data Dashboard here: bit.ly/4j21CpP @HQIP @JillStoddart @lymphomahub @LLSusa @LymphomaAction @lymphoma @DavidJCutter @NHSEngland @AnthonyNolan @bloodcancer_uk @BloodCancer_Res #data #NHL #Cancer
4
5
262
📢Our latest newsletter provides updates on: State of the Nation reporting, our Quarterly Clinical Performance Indicator report, the recent @NATCAN_news webinar & details of the latest report from @bloodcancer_uk 📰 bit.ly/4i2c1Br @HQIP @LymphomaAction @Ed_Pinches #NHL
1
2
7
992
Out this week, this new publication explores how the distribution of trial site locations, may lead to disparities in patient representation in clinical trials. bit.ly/416VENC @DavidJCutter @LymphomaAction @bloodcancer_uk @NATCAN_news @WileyGlobal @NHSEngland @HQIP
2
4
155
Having learned every @BritSocHaem guideline off by heart for my FRCPath, it was very exciting to have been afforded the opportunity to lead an amazing group of co-authors for our GPP regarding bleomycin use in Hodgkin Lymphoma- published today! onlinelibrary.wiley.com/doi/…

Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients...

Recommendations from the British Society of Haematology regarding bleomycin pulmonary toxicity (BPT) in classical Hodgkin lymphoma (CHL) centre around (1) appropriate patient selection, (2) routine...

onlinelibrary.wiley.com
2
15
2
51
7,407
Moving beyond mean heart dose: The importance of cardiac substructures in radiation therapy toxicity. onlinelibrary.wiley.com/doi/…
20
51
3,644
Steve Ansell highlighting late effects of our treatment. No ‘safe dose’ of dox with respect to cardiac toxicity. Good data for dexrazoxane cardio protection with no evidence of ‘tumour protection’. #ISHL13 #lymsm
1
7
1
18
2,529
Abscopal effect does exist in #Hodgkin lymphoma when RT 20Gy is given to PD-1 treated patiens. New distant responses seen outside RT fields. Pembro-RT an option in R/R HL with limited disease #ISHL13 #lymsm dr Christian Bauses. Also safe with RT with low doses! AERN trial !
3
16
1,036
Thanks to Rajana Advani for including our data in the Best of #ISHL13 session. What a phenomenal three days- so much exciting science and practice-changing trial data, and so many new friends made with exciting future collaboration potential.
1
4
13
1,781
Great presentation by @ABarrettHaem on the NHSE dataset of older pts with Hodgkin lymphoma. ABVD assoc with best outcomes but of course used in fitter pts. Profound impact of age, PS, comorbidities in this age group. #ISHL13 #lymsm
6
3
18
3,374
Fascinating - the hospital at which a patient with Hodgkin lymphoma is treated in England has more effect on the variation in radiotherapy usage than sex of the patient. Suggests standardisation of approach is not yet achieved! #ISHL13 #lymsm. @DavidJCutter @DavidAdrwJones
1
2
8
1,762
Excited to be here at #ISHL13 , come along Sunday at 3pm for my talk about our registry analysis @DavidJCutter and swing by our posters regarding translational analysis of the ANIMATE study and our data collection project HoOP @graham74GC #hodgkinlymphoma
1
4
1
18
2,942
We promised you something exciting was coming... Our first quarterly report which includes clinical performance indicators & is presented on a new,highly interactive dashboard! 💥 bit.ly/3Ni3PyL @HQIP @LymphomaAction @bloodcancer_uk @DavidJCutter @KateWalkerLon #NHL
2
2
210
Watch this space! 👀Our latest NNHLA quarterly report is out tomorrow. We won't spoil the surprise, but we've been working on some changes and this time something is different!..... 🤫🏥📊🔎 @HQIP @JillStoddart @bloodcancer_uk @LymphomaAction @BritSocHaem @DavidJCutter
1
1
3
329
📢💥It's here! We are delighted to share our first State of the Nation report; along with a number of supplementary materials. Our thanks to everyone involved in its development. bit.ly/3XmI5q7 @HQIP @LymphomaAction @bloodcancer_uk @DavidJCutter @KateWalkerLon
3
1
5
858
Exciting news! ⭐️The first NNHLA State of the Nation report is out tomorrow! Check this space or the @NATCAN_news webpages for details bit.ly/3TkRE7J #BCAM @LymphomaAction @bloodcancer_uk @LLSusa @AnthonyNolan @HQIP @NHSEngland @DavidJCutter @macmillancancer @MJAhearne
3
6
457
The NNHLA Quality Improvement Plan has landed! The plan sets out: ⭐️5 QI goals ⭐️11 performance indicators Read the full report here bit.ly/3AKNvmX @LymphomaAction @LLSusa @bloodcancer_uk @BritSocHaem @AnthonyNolan @HQIP @JillStoddart @DavidJCutter @KateWalkerLon

NNHLA Quality Improvement Plan 2024 - National Cancer Audit Collaborating Centre

NNHLA Quality Improvement Plan 2024 The Quality Improvement Plan describes the approach taken across the NATCAN cancer audits to develop improvement goals and performance indicators, ensuring these...

natcan.org.uk
National Cancer Audit Collaborating Centre@NATCAN_news5 Sep 2024
📢 The new Quality Improvement (QI) Plans are live! Read them here bit.ly/4gag9OL💡 The audits have developed key QI goals and performance indicators to monitor progress, aiming for these to be measurable, actionable, and improvable. @RCSnews @HQIP @NHSEngland @LSHTM
1
5
249
Load more